InMed announces progress on COPD program

VANCOUVER, Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announced progress today on its R&D program in the use of cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD). In June, 2015 InMed initiated its COPD program using its bioinformatics analysis tool to identify the targets and potential active compounds that can be useful for the treatment of COPD. Subsequently, with in vitro assays using human lung fibroblasts (HFL-1 cell line), InMed has demonstrated that certain cannabinoid compounds are capable of affecting a specific protein in the biochemical pathway relevant to healing and fibrosis in the lung. 

Dr. Sazzad Hossain, Chief Scientific Officer of InMed, noted, "Taking into consideration the impact of this specific protein's role in lung tissue remodeling and fibrosis, these preliminary data are important and promising for developing cannabinoid-based therapies for COPD." It is well known that cannabinoids exhibit bronchodilatory, immunosuppressive, and anti-inflammatory properties and thus cannabinoid-based therapies may offer safer and more effective treatment options for COPD.

"We continue to make significant scientific progress that further validates InMed's proprietary bioinformatics analysis tool as a cost-effective way to identify drug-disease targets and expedite their validation in pre-clinical models," added Dr. Ado Muhammed, Chief Medical Officer of InMed.  "In addition to our primary drug development programs in Epidermolysis Bullosa and Glaucoma, we are pleased to continue to expand the role of cannabinoids in other disease areas."

About Dr. Hossain
Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development at institutions including the University of British Columbia, National Research Council of Canada and Xenon Pharmaceuticals. He is the author of more than 40 peer-reviewed papers, primarily in pharmacology, genetics and nutritional sciences.

About Dr. Muhammed
Dr. Muhammed has extensive R&D and clinical experience in the development of cannabinoid therapies. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based pharmaceutical company that has pioneered the cannabis-based medicines sector. He is a Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.

About InMed
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Cautionary Note Regarding Forward-Looking Information

Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE InMed Pharmaceuticals Inc.